The workspace for preclinical decisions

Discuss your programmeSee how it works
The Octopus candidate comparison screen, showing a ranked compound list with observed and predicted pIC50 for each analogue.

How it works

01 / 04

Evaluate activity, selectivity, DMPK and safety against programme criteria, with measured and predicted results clearly distinguished.

Every conclusion, open to review

Trace conclusions to their sources, experimental conditions and model versions. Review applicability and uncertainty, with observations, predictions and mechanistic hypotheses kept separate.

Request a demo

A worked example

Programme
Covalent KRAS G12C series, 214 analogues
Decision examined
Which analogue carries the exposure margin to a toxicology study
Measurements available
Covalent kinetics, HLM stability, free fraction, permeability, hERG, CYP3A4 TDI
Limiting finding
Margin capped by CYP3A4 oxidation at the position being used as a potency handle
Recommendation
Advance OPS-SM-118, at 11x unbound margin and 12 percent lower covalent potency
Validation status
Confirmed by metabolite identification; rat margin remains at 1.7x and open
Read the full case study

Bring one programme into Octopus

We start from the data you already hold, and show what it supports before anything new is run.

Discuss your programme